www.boehringer-ingelheim.com
#2
Value through Innovation
O U R C O M P A N Y
D I V E R S I T Y & I N C L U S I O N D R I V E I N N O V A T I O N
M A K I N G M O R E H E A L T H
H U M A N P H A R M A C E U T I C A L S
S U S T A I N A B L E E C O N O M I C & S C I E N T I F I C A C T I V I T YS U C C E S S F U L B U S I N E S S E S
A N I M A L H E A L T H ( A S O F 0 1 . 0 1 . 2 0 1 7 )
B I O P H A R M A C E U T I C A L C O N T R A C T M A N U F A C T U R I N G
E C O N O M I C S U C C E S S ( 2 0 1 6 )
R E S E A R C H & D E V E L O P M E N T
Founded in 1885 in Ingelheim and family-owned to this day
Biopharma
47%women* 33%
G E N E R A T I O N Y ( 1 9 8 1 - 2 0 0 0 ) *
Respiratory diseases
N E T S A L E S
R E T U R N O N N E T S A L E S
35% female leaders*
EUR 2,870million
Prescription Medicines expenditure in research &
development in 2016
A M E R I C A S
≜ around
23.8% of Prescription Medicines
net sales 2016
EUR 613 million T O T A L N E T
S A L E S 2 0 1 6
EUR 1,460 million* T O T A L N E T S A L E S *net sales (2016) prior to the
integration of Merial
EUR
6,542 million
EUR
5,082million
EUR
4,226million
18.1%EUR 15,850 million
EUR 12,036 million T O T A L N E T S A L E S
P R E S C R I P T I O N M E D I C I N E S 2 0 1 6
E U R O P E A S I A , A U S T R A L I A , A F R I C A ( A A A )
Making More Health is a global initiative by Boehringer Ingelheim in cooperation with Ashoka, a non-governmental organ-isation. Its aim is to improve healthcare for people worldwide.
Boehringer Ingelheim is a world-leading contract manufacturer of biopharmaceuticals.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies.
Human pharma
of biopharmaceutical production sites in Europe, the USA and Asia
Animal health
F O C U S O N
F O C U S O N
Oncology
G L O B A L P L A Y E R
We have manufactured M O R E T H A N
25B I O P H A R M A C E U T I C A L S
for global markets
~ 50,000 employees worldwide at present
M O R E T H A N
80social entrepreneurs in over 30 countries
received support since 2010
A P P R O X .
3,700 Boehringer Ingelheim employees
worldwide are involved in the initiative
Central nervous system + immunology
Cardiometabolic diseases
D I V E R S I T Y I S A L S O A B O U T
54% P E T S
5% E Q U I N E
17% C A T T L E
16% S W I N E
8% P O U L T R Y
S H A R E
59% C O M P A N I O N
A N I M A L S41% L I V E S T O C K
Team composition
Innovation / growth
Balance
D I V E R S I T Y I S N O T O N L Y A B O U T
Compliance / ethics
Minorities Individuals S O C I A L R E S P O N S I B I L I T Y
Focus on research therapeutic areas
Scientific platforms
Research Beyond Borders
We operate
1G L O B A L N E T W O R K We are a pioneer in
biopharmaceuticals W I T H O V E R
35Y E A R S
of experience
3 P I L L A R S
17% B A B Y B O O M E R S ( 1 9 4 6 - 1 9 6 4 ) *
50% G E N E R A T I O N X ( 1 9 6 5 - 1 9 8 0 ) *
* Boehringer Ingelheim worldwide, 2016
